Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
STAR
Mr. Badree Komandur · Bengaluru, India · 3,535 employees
₹1,060.00
▲+1.76%STAR is a mid-cap pharmaceutical company trading below its 52-week high with solid profitability metrics but facing moderate growth headwinds.
Exchange
NSI
Currency
INR
Day range
₹1,041.00 – ₹1,087.20
52-week range
₹768.65 – ₹1,231.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears fairly valued relative to its P/E of 17.58, trading in the middle of its 52-week range, with current pricing reflecting its moderate growth prospects and solid profitability.
13.9% below the 1-year high · trend down
Hedge-fund memo
Today
Stock is up 1.76% today, trading within its daily range with moderate volume.
This week
No significant weekly movement indicated in the data provided.
This month
No significant monthly movement indicated in the data provided.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
24 headlines · 18 outlets · 7d
The Conversation·1d ago·political uncertainty
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| STAR | 97.70B | 17.58 | 20.03% | 8.56% | 11.20% |
| WOCKPHARMA | 311.42B | 146.97 | 4.00% | 22.01% | 36.40% |
| TORNTPHARM | 1.85T | 76.23 | 16.99% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory hurdles for drug approvals
Mitigation: Diversify pipeline and invest in compliance infrastructure
Pricing pressure in generic markets
Mitigation: Focus on higher-margin specialty products and emerging markets
Business intelligence
Competitive moat
Established manufacturing capabilities and distribution network provide competitive advantage in the Indian pharmaceutical market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
FDA approvals for pipeline products
Expansion in emerging markets
Thesis builder
Bull case
Strong profitability and established market position could drive re-rating if growth accelerates.
Base case
Stable performance with moderate growth maintaining current valuation.
Bear case
Intense competition and regulatory challenges could pressure margins and growth.
Time horizon
12-18 months
Est. CAGR
8-12%
Entry (qual.)
Consider on dips below 900 INR for better risk-reward
Exit (qual.)
Exit if breaks below 800 INR or fails to sustain above 52-week high
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how STAR fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain STAR for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Hold with a wait-and-see approach for clearer directional signals.
scanx.trade·1d ago·investor meeting scheduled
scanx.trade·1d ago·profit up 25% YoY
The Hindu·1d ago·celebrity death unrelated
Goal.com·1d ago·sports entertainment value
autopunditz.com·1d ago·product safety rating high
NPR·1d ago·celebrity death unrelated
DriveSpark·1d ago·profit up 25% YoY
Sahi·1d ago·celebrity unrelated
The Times of India·1d ago·sports unrelated
The Times of India·1d ago·celebrity unrelated
NDTV·1d ago·sports unrelated
The Times of India·1d ago·celebrity unrelated
The Economic Times·1d ago·social media unrelated
The IX Sports·1d ago·sports unrelated
Goal.com·1d ago·sports transfer news
Variety·1d ago·celebrity death unrelated
Motoroids·1d ago·product safety rating high
Goal.com·1d ago·sports transfer news
The Times of India·1d ago·celebrity unrelated
Hotelier India·1d ago·flight service resumption
Hindustan Times·1d ago·luxury hospitality unrelated
RushLane·1d ago·product safety rating high
NL Times·1d ago·scientific discovery unrelated
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 20.20% |
| 41.80% |
| AJANTPHARM | 424.34B | 40.17 | 25.39% | 23.19% | 21.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,041.00
Resistance (day/52w high)
₹1,087.20
Volume
1,51,300
Trend
down
RSI (14)
45
MACD
bearish
MA cross
golden
50-day MA
₹1,085.37
200-day MA
₹968.99
vs 200-DMA
9.4%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.